KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Total Non-Current Liabilities (2017 - 2025)

Historic Total Non-Current Liabilities for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $2.8 billion.

  • Amneal Pharmaceuticals' Total Non-Current Liabilities rose 1585.76% to $2.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 billion, marking a year-over-year increase of 1585.76%. This contributed to the annual value of $2.4 billion for FY2024, which is 578.86% down from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Total Non-Current Liabilities stood at $2.8 billion for Q3 2025, which was up 1585.76% from $2.4 billion recorded in Q2 2025.
  • Amneal Pharmaceuticals' 5-year Total Non-Current Liabilities high stood at $2.9 billion for Q2 2021, and its period low was $2.3 billion during Q1 2025.
  • In the last 5 years, Amneal Pharmaceuticals' Total Non-Current Liabilities had a median value of $2.8 billion in 2023 and averaged $2.7 billion.
  • Per our database at Business Quant, Amneal Pharmaceuticals' Total Non-Current Liabilities plummeted by 1244.32% in 2024 and then skyrocketed by 1585.76% in 2025.
  • Over the past 5 years, Amneal Pharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $2.9 billion in 2021, then fell by 1.42% to $2.8 billion in 2022, then dropped by 9.62% to $2.6 billion in 2023, then decreased by 5.79% to $2.4 billion in 2024, then grew by 15.05% to $2.8 billion in 2025.
  • Its last three reported values are $2.8 billion in Q3 2025, $2.4 billion for Q2 2025, and $2.3 billion during Q1 2025.